Trial Profile

ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with or without platinum-based chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Platinum complexes
Indications Solid tumours
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

02 Jan 2024 Status changed from recruiting to active, no longer recruiting.
19 Apr 2023 Results (n=16), evaluating the safety of the radiolabeled LAG-3 antibody 89Zr-DFO-REGN3767, to determine the optimal tracer dose and imaging time point, presented at the 114th Annual Meeting of the American Association for Cancer Research
06 Dec 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com